IDEAYA Biosciences and French pharma company Servier said ​on Monday their combination drug for a type of eye cancer met the ‌main goal of a mid-to-late-stage trial, sending the U.S. biotech's shares ...

A closely watched clinical trial testing a new two-drug combination against metastatic uveal melanoma, the deadliest form of ...

A phase 2/3 trial of Ideaya Biosciences and Servier’s eye cancer candidate has hit its primary endpoint, teeing up a filing for accelerated FDA approval in the second half of th ...

Servier $210 million bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as the drug has hit the mark in a phase 2/3 that could form the basis of regulatory filings later this ...

IDEAYA Biosciences (IDYA) stock jumped 26% after its eye cancer drug combo doubled progression-free survival in a Phase 2/3 trial versus standard care.

How Merck keeps the price of its lifesaving cancer drug, Keytruda, sky-high, locking out patients and squeezing health care ...

The study, published in Cell Reports Medicine, suggests that zeaxanthin — a plant-derived carotenoid — could enhance the body ...

IDEAYA Biosciences Inc. IDYA shares are up during Monday’s premarket session following the announcement of positive topline results from the Phase 2/3 trial for darovasertib in combination with ...

Washington: The researchers at the University of Chicago have uncovered a surprising new role for zeaxanthin, a plant-based ...

The Hall of Famer said while his career was thriving, his skin was being damaged. And, in 2013 he was diagnosed with stage 3 ...

ESPN college basketball analyst Dick Vitale shared another health update on Monday in which he announced he was diagnosed ...

What is the Cancer Calculus investigation? The Cancer Calculus is a yearlong investigation by the International Consortium of ...